KM Pharmaceutical Publishes CEO's Shareholder Letter: "All-Out Effort to Restore Corporate Value through Responsible Management"

KM Pharmaceutical has expressed its position regarding designation as an issue management stock through a shareholder letter from its CEO, emphasizing its commitment to restoring corporate value based on responsible management and transparent communication.

On July 15, KM Pharmaceutical announced that it had released a shareholder letter signed by CEO Baek Seungwon and explained to shareholders the company's future management direction and plans to resolve its issue management status.

In the letter, CEO Baek stated, "I feel a heavy sense of responsibility as CEO for the deep concern caused to our shareholders by the recent issue management designation. I am treating the current situation with utmost seriousness, making the resolution of the designation and the recovery of corporate value our top management priorities, and will mobilize all available resources to achieve them."

The shareholder letter outlines key management strategies, including a third-party paid-in capital increase directly participated in by the CEO, improvement of the financial structure through asset restructuring, advancement of production facilities and expanded investment in research and development, as well as strengthening the competitiveness of the OEM・ODM business.

The company explained that the CEO's direct participation in the capital increase is a decision that demonstrates not only a means of raising funds, but also the CEO's confidence in the company's future growth and value, as well as a commitment to responsible management.

The funds secured through the paid-in capital increase will be primarily used to advance production facilities, invest in research and development, and stabilize the financial structure. Based on this, the company plans to strengthen its existing manufacturing competitiveness while also continuing to expand its OEM・ODM business and pursue a profitability-focused business strategy.

CEO Baek said, "Rather than being a company that only shares good news, I will be honest and communicate progress as it is, whether it is significant or not. I believe that regaining the trust of shareholders starts with transparent communication."

He added, "I will do my best to ensure that the trust of our shareholders, who believe in and wait for the company, is not betrayed through responsible management and continuous enhancement of corporate value."

The company is also actively seeking asset restructuring and strategic growth opportunities, and stated that it is considering all possible options to have the issue management designation lifted.

A company official said, "Following the release of the shareholder letter, we have received messages of support expressing agreement with the CEO's commitment to responsible management and transparent communication, along with expectations for tangible performance. We will continue to strengthen communication with the market and our shareholders going forward."

KM Pharmaceutical plans to restore market trust through direct capital injection by the CEO and strengthened shareholder communication, and to focus on recovering corporate value by improving the financial structure and enhancing business competitiveness.

This content was produced with the assistance of AI translation services.